CRISP3 Antibody

What is CRISP3 and why is it significant in research contexts?

CRISP3 (also known as SGP28) is a glycoprotein belonging to the family of cysteine-rich secretory proteins (CRISPs), originally discovered in human neutrophilic granulocytes. It is widely distributed in exocrine glands (salivary glands, pancreas, and prostate), eosinophilic granulocytes, and to a lesser extent in epididymis, ovary, thymus, and colon . The presence of CRISP3 in neutrophils, eosinophils, and exocrine secretions indicates its potential role in innate host defense . Research significance stems from its upregulation in certain pathologies, particularly in prostate cancer, making it a potential biomarker and therapeutic target .

What are the optimal protocols for CRISP3 antibody-based immunohistochemistry?

For optimal immunohistochemistry (IHC) using CRISP3 antibodies, researchers should follow these methodological steps:

• Tissue preparation: Use formalin-fixed paraffin-embedded tissue sections (4 μm thick)

• Antigen retrieval: Two validated methods are available:

  • Heat-induced antigen retrieval using Epitope retrieval solution 1 for 20 minutes

  • Alternative method using TE buffer pH 9.0 or citrate buffer pH 6.0

• Primary antibody incubation: Optimal conditions vary by antibody:

  • For rabbit polyclonal antibody: 1:100 dilution for 15 minutes at room temperature

  • For mouse monoclonal antibody (MAB23971): 15 µg/mL overnight at 4°C

• Detection system: Bond polymer Refine Detection kit with DABi detection and counter stain

• Scoring system: A comprehensive scoring approach includes:

  • Negative(0): absence of CRISP3 staining in 100% of cells

  • Weak(1): intensity of 1+ in >70% of tumor cells or staining intensity of 2+ in ≤30% of tumor cells

  • Moderate(2): intensity of 1+ in >70% of tumor cells, or staining intensity of 2+ in >30% but ≤70% of tumor cells, or staining intensity of 3+ in ≤30% of tumor cells

  • Strong(3): intensity of 2+ in >70% of tumor cells or staining intensity of 3+ in >30% of tumor cells

Note: When evaluating CRISP3 expression, researchers should use adjacent stromal cells as an internal control for measuring relative expression of epithelial cells .

How should Western blot protocols be optimized for CRISP3 detection?

For optimal Western blot detection of CRISP3:

• Sample selection: CRISP3 has been successfully detected in:

  • Human saliva

  • Human placenta tissue

  • Jurkat cells

  • Mouse tissues: colon, ovary, thymus

• Antibody dilution ranges:

  • Recommended range: 1:1000-1:4000 for polyclonal antibodies

  • Always titrate in each testing system to obtain optimal results

• Expected molecular weight bands:

  • Calculated molecular weight: 28 kDa

  • Observed molecular weight: 29 kDa

  • Two species may be detected: 30 kDa (glycosylated) and 28 kDa (non-glycosylated)

• Cross-reactivity considerations:

  • Some antibodies show 50-100% cross-reactivity with recombinant human CRISP-2

  • Controls should be selected accordingly

How can CRISP3 antibodies be used to investigate the relationship between CRISP3, ERG, and PTEN in prostate cancer research?

CRISP3 antibodies are valuable tools for investigating the molecular subtyping of prostate cancer, particularly in relation to ERG gene rearrangements and PTEN deletions:

• Experimental approach:

  • Implement a multiplex immunohistochemistry protocol that allows simultaneous detection of CRISP3, ERG, and PTEN

  • Use tissue microarrays (TMAs) to evaluate multiple samples concurrently

• Key research findings:

  • CRISP3 protein expression is significantly associated with ERG expression (69% in ERG positive vs. 58% in ERG negative, p=0.002)

  • CRISP3 protein expression is significantly associated with PTEN deletions (71% vs. 58%, p=0.01)

  • Higher CRISP3 protein expression correlates with the degree of PTEN genomic aberrations (intact vs. hemizygous vs. homozygous deletions)

• Mechanistic insights:

  • ERG transcription factor directly binds to the CRISP3 promoter through three putative ETS-binding-sites, establishing a direct regulatory link between ERG and CRISP3

  • CRISP3 and ERG show two-fold increase in VCaP cell line which harbors TMPRSS2-ERG rearrangement

• Clinical implications:

  • CRISP3 mRNA expression is associated with biochemical recurrence in prostate cancer (p=0.038 in MSKCC cohort)

  • CRISP3 mRNA expression is related to lethal disease (p=0.0086 in Swedish cohort)

  • CRISP3 mRNA expression retains prognostic value in the subgroup of patients with Gleason Score 6 & 7

This research approach enables molecular subtyping of prostate cancer based on the combined status of CRISP3, ERG, and PTEN.

What are the methodological considerations for studying CRISP3 in inflammatory processes?

When investigating CRISP3's role in inflammation, particularly in conditions like adult varicocele:

• Sample preparation:

  • For seminal plasma analysis, collect samples following standardized protocols

  • Process samples to isolate seminal plasma by centrifugation

  • Store at appropriate temperatures to maintain protein integrity

• Detection methodology:

  • Western blotting is the recommended method for distinguishing between CRISP3 isoforms

  • Both 29 kDa and 31 kDa isoforms should be assessed separately

  • Standardized loading controls should be implemented

• Study design considerations:

  • For intervention studies (e.g., varicocelectomy), implement a pre-post design to measure changes in CRISP3 levels

  • Include appropriate control groups to account for natural variations

  • Collect comprehensive clinical data to correlate with CRISP3 levels

• Interpretation guidelines:

  • Elevated CRISP3 levels may indicate an inflammatory state

  • Consider the persistence of elevated CRISP3 as a potential marker of chronic inflammation

  • Analyze whether interventions (e.g., varicocelectomy) normalize CRISP3 levels, indicating resolution of the inflammatory state

How can researchers address cross-reactivity issues with CRISP3 antibodies?

Cross-reactivity is a significant concern with CRISP3 antibodies, particularly with CRISP2:

• Cross-reactivity profile:

  • Some monoclonal antibodies (e.g., clone 295203) show 50-100% cross-reactivity with recombinant human CRISP-2 in direct ELISAs and Western blots

  • Polyclonal antibody 14847-1-AP can recognize both CRISP2 and CRISP3

• Validation strategies:

  • Knockout/knockdown controls: Implement CRISP3 knockdown or knockout controls to confirm antibody specificity

  • Recombinant protein competition: Pre-incubate antibodies with recombinant CRISP3 to block specific binding

  • Comparative analysis: Test multiple antibodies targeting different epitopes of CRISP3

  • Mass spectrometry confirmation: For critical experiments, confirm identity of detected proteins by mass spectrometry

• Application-specific recommendations:

  • For Western blot: Use multiple antibodies and compare band patterns

  • For IHC: Include appropriate positive and negative tissue controls

  • For ELISA: Implement calibration curves with recombinant proteins to assess cross-reactivity

• Reporting guidelines:

  • Always document the specific antibody clone used

  • Report known cross-reactivity in methods sections

  • Consider the biological relevance of potential cross-reactive proteins in the experimental system

What are the critical parameters for CRISP3 antibody validation in different experimental systems?

Comprehensive validation of CRISP3 antibodies should include:

• Sensitivity and specificity assessment:

  • Determine limit of detection using recombinant CRISP3 protein

  • Evaluate cross-reactivity with related proteins (especially CRISP2)

  • Test in cell lines with known CRISP3 expression profiles

• Application-specific validation:

  • For IHC: Validate antibody performance with:

    • Tissue microarrays containing positive controls (prostate, salivary glands)

    • Negative controls (tissues with minimal CRISP3 expression)

    • Multiple fixation and antigen retrieval methods

  • For Western blot: Confirm:

    • Correct molecular weight detection (28-30 kDa)

    • Detection in validated positive samples (human saliva, placenta tissue, Jurkat cells)

    • Linear response range and appropriate loading amounts

• Lot-to-lot consistency testing:

  • Implement standard samples for testing each new antibody lot

  • Document and maintain reference data for cross-comparison

  • Consider creating internal reference standards

• Validation in disease-relevant contexts:

  • For prostate cancer research: Validate using both normal prostate and prostate cancer tissues

  • For inflammation studies: Confirm detection in neutrophil and eosinophil samples

  • For reproductive biology: Validate in relevant reproductive tissue samples

How can researchers use CRISP3 antibodies to explore its role in innate immunity?

To investigate CRISP3's role in innate immunity:

• Experimental approaches:

  • Cell-specific localization: Use immunofluorescence with co-staining for neutrophil and eosinophil markers to assess cell-specific expression

  • Stimulation experiments: Measure CRISP3 release from granulocytes following various stimuli using ELISA or Western blot

  • Functional assays: Implement neutralizing antibodies to block CRISP3 function in immune response assays

• Research contexts to explore:

  • Secretory pathways: Investigate CRISP3 trafficking and secretion in neutrophils and exocrine cells

  • Antimicrobial activity: Assess CRISP3's potential antimicrobial properties in various infection models

  • Inflammatory signaling: Examine CRISP3's role in modulating inflammatory pathways

• Methodological considerations:

  • Use both glycosylated and non-glycosylated recombinant CRISP3 in functional studies

  • Consider the formation of protein complexes with alpha 1B-glycoprotein and beta-microseminoprotein/PSP94

  • Implement tissue-specific knockout models to assess function in specific physiological contexts

What is the current understanding of CRISP3 structure-function relationship and how can researchers investigate it?

Current understanding and research approaches for CRISP3 structure-function studies:

• Structural features:

  • CRISP3 consists of an N-terminal SCP domain, a hinge region, and a cysteine-rich domain

  • Contains 16 invariant cysteine residues that form eight disulfide bonds

  • Exists in both glycosylated (30 kDa) and non-glycosylated (28 kDa) forms

• Functional domains:

  • The SCP domain mediates binding to alpha 1B-glycoprotein and beta-microseminoprotein/PSP94

  • The cysteine-rich domain may be involved in regulatory functions

  • Glycosylation may influence protein-protein interactions but is not required for binding

• Research methodologies:

  • Domain-specific antibodies: Generate and use antibodies targeting specific domains to assess their functions

  • Recombinant domain studies: Express individual domains to evaluate their specific activities

  • Site-directed mutagenesis: Modify key residues (particularly cysteines) to assess their role in structure and function

  • Interactome analysis: Use co-immunoprecipitation with CRISP3 antibodies followed by mass spectrometry to identify interaction partners

• Technical considerations:

  • Preserve native disulfide bonding in recombinant expression systems

  • Consider both glycosylated and non-glycosylated forms in functional studies

  • Implement structural biology approaches (X-ray crystallography, cryo-EM) to resolve detailed structure